Navigation Links
MD Bioproducts Releases a New Mouse T1/ST2 ELISA
Date:3/29/2010

New ELISA offers a rapid method to quantitate T1/ST2 from mouse serum and cell culture supernate samples.

(PRWEB) March 24, 2010 -- MD Bioproducts, a division of MD Biosciences, Inc announces the launch of its new Mouse T1/ST2 ELISA for the study of inflammatory conditions. The ELISA offers researchers a rapid and accurate method to measure mouse serum and cell culture supernate levels of T1/ST2. The assay measures samples in the range of 0.156 – 10 ng/mL with a sensitivity of 0.05 ng/mL. Results can be obtained in less than 3 hours. In addition to the T1/ST2 ELISA, MD Bioproducts also offers researchers T1/ST2 antibodies for other related research applications such as IHC, western blotting, and flow cytometry.

ST2, also know as IL-1 R4 and T1 is an interleukin-1 receptor family glycoprotein that contributes to Th2 immune responses. ST2 is expressed on the surface of mast cells, activated Th2 cells, macrophages and cardio myocytes. It binds IL-33, a cytokine that is up regulated by inflammation or mechanical strain in smooth muscle cells, keratinocytes, airway epithelia and cardiac fibroblasts. The soluble ST2 isoform is released by activated Th2 cells and strained cardiac myocytes and is elevated in the serum in allergic asthma. The roles of T1/ST2 and IL-33 have been investigated in many immune responses such as allergy, asthma, rheumatoid arthritis and osteoarthritis.

About MD Bioproducts
MD Bioproducts is a division of the privately-owned company MD Biosciences, Inc. offering products for use in the inflammations, neurology, endocrinology, and metabolic disorders research fields. Since beginning operations in the U.S., based out of St. Paul, Minnesota, MD Biosciences has experienced significant development and grown to a company of 60 employees.

About MD Biosciences
MD Biosciences provides pre-clinical contract research services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.

###

Read the full story at http://www.prweb.com/releases/mdbioproducts/ST2ELISA/prweb3769704.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. BioEnergy International, LLC Acquires Assets of OmniGene Bioproducts, Inc.
2. Microbia PE Bolsters Senior Management Team; Positions Company for Commercializing Proprietary Bioproducts
3. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1
4. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
5. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
6. ARUP Laboratories Releases ARUP Consult(R) 2.0
7. Rabobank Releases Annual North American Food & Agribusiness Outlook
8. National Nanotechnology Initiative releases new strategic plan
9. Seven Summits Research Releases Alerts on XOM, MER, DRYS, CSC, and PDLI
10. CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases
11. BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
MD Bioproducts Releases a New Mouse T1/ST2 ELISA
(Date:3/23/2017)... , March 23, 2017  GlobeImmune, Inc. today announced ... the sale of 12,835,490 shares of its common stock ... of companies. In connection with the sale of its common ... cash and issue to GlobeImmune 200,000 shares, an estimated ... "We are pleased to enter into this ...
(Date:3/23/2017)... SEATTLE , March 23, 2017 ... translational development of novel therapies in immuno-oncology, today ... to lead" small molecule compounds that activate interferon ... (RLR) pathways and demonstrate immune-mediated tumor regression in ... in the study who demonstrated complete tumor regression ...
(Date:3/23/2017)... March 23, 2017  Agriculture technology company Cool Planet ... and note conversion to commercialize its Cool Terra and ... on developing products that are simultaneously profitable as well ... the last 18 months. This latest round of funding ... Partners. The company,s primary product, Cool ...
(Date:3/22/2017)... March 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), ... Center (RGC), U.K. Biobank and GSK to generate genetic sequence ... resource. The initiative will enable researchers to gain valuable insights ... a wide range of serious and life threatening diseases. ... Genetic evidence ...
Breaking Biology Technology:
(Date:3/9/2017)... , March 9, 2017 4Dx has publicly ... Lung Imaging Workshop at the University of Pennsylvania. Founder ... to deliver the latest data to world leaders in ... brings together leaders at the forefront of the industry ... imaging. "The quality of the imaging ...
(Date:3/2/2017)... Summary This report provides all the ... interests and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ...
(Date:2/28/2017)... LOS ANGELES , Feb. 28, 2017   ... identity verification software globally, announces significant enhancements to new ... in May 2016. New products include mobile and desktop ... and DocX TM - a real time manual ... Acuant,s core idScanĀ® technology provides the fastest and most ...
Breaking Biology News(10 mins):